Management of Complex Treatment-resistant Psychotic Disorders

Herausgeber: Cummings, Michael; Stahl, Stephen

• Broschiertes Buch

Produktbeschreibung

An accessible, evidence-based guide for psychiatrists and mental health professionals involved in the treatment of patients with challenging psychotic disorders. Includes chapters on treating psychosis and bipolar diathesis, along with essential information on treatment strategies, pharmacological information, and tips for managing common issues.

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Verlag: Cambridge University Press
• Seitenzahl: 546
• Erscheinungstermin: 2. Oktober 2023
• Englisch
• Abmessung: 229mm x 152mm x 30mm
• Gewicht: 868g
• ISBN-13: 9781108965682
• ISBN-10: 1108965687
• Artikelnr.: 60747548

Inhaltsangabe

Part I. Treatment Strategies: 1.01. Approaches to positive Psychotic symptoms
1.02. Use of plasma levels in Antipsychotic and Mood Stabilizer treatment
1.03. Advantages of long-acting injectable Antipsychotics
1.04. Approach to Schizophrenia Spectrum treatment-resistant patients
1.05. Approach to depressed or suicidal Schizophrenia Spectrum patients
1.06. Approach to persistent aggression and violence in Schizophrenia Spectrum Disorders
1.07. Approach to treatment of Bipolar Diathesis in Schizophrenia Spectrum patients
1.08. Approach to Anxiety in Schizophrenia Spectrum patients
1.09. Approach to Insomnia and Sleep Disturbance in Schizophrenia Spectrum disorders
1.10. Approach to Psychosis in children and adolescents
1.11. Electro-convulsive therapy and other Non-pharmacological treatments
1.12. Approach to substance use disorders in Schizophrenia Spectrum Disorders
1.13. Approaches to Behavioral Disturbances and Dementia and TBI patients
Part II. Medication Reference Tables: First-generation (Typical) Antipsychotics: 2.01. Chlorpromazine
2.02. Fluphenazine
2.03. Haloperidol
2.04. Loxapine
2.05. Perphenazine
2.06. Thiothixene
2.07. Trifluoperazine
Second-generation (Atypical) Antipsychotics: 2.08. Asenapine
2.09. Clozapine
2.10. Iloperidone
2.11. Lumateperone
2.12. Lurasidone
2.13. Olanzapine
2.14. Paliperidone
2.15. Quetiapine
2.16. Risperidone
2.17. Ziprasidone
Dopamine Partial Agonist Antipsychotics (Arias): 2.18. Aripiprazole
2.19. Brexpiprazole
2.20. Cariprazine
Medications for Motor/Neurologic Adverse Effects: 2.21. Amantadine
2.22. Benztropine
2.23. Diphenhydramine
2.24. Trihexyphenidyl
Mood Stabilizers: 2.25. Carbamazepine
2.26. Lamotrigine
2.27. Lithium
2.28. Valproic Acid
Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants: 2.29. Citalopram
2.30. Escitalopram
2.31. Fluoxetine
2.32. Fluvoxamine
2.33. Paroxetine
2.34. Sertraline: SSRI/5HT-1 Partial Agonist Antidepressants: 2.35. Vilazodone
2.36. Vortioxetine
Serotonin/Norepinephrine Reuptake Inhibitor (SNRI) Antidepressants
2.37. Desvenlafaxine
2.38. Duloxetine
2.39. Levomilnacipran
2.40. Venlafaxine
Mixed Mechanism Antidepressants: 2.41. Bupropion
2.42. Mirtazapine
2.43. Trazodone
Tricyclic Antidepressants: 2.44. Amitriptyline
2.45. Clomipramine
2.46. Desipramine
2.47. Doxepin
2.48. Imipramine
2.49. Nortriptyline
Monoamine Oxidase Inhibitor (MAOI) Antidepressants: 2.50. Isocarboxazid
2.51. Moclobemide
2.52. Phenelzine
2.53. Transdermal Segeliline
2.54. Tranylcypromine
Anxiolytics: 2.55. Alprazolam
2.56. Buspirone
2.57. Clonazepam
2.58. Diazepam
2.59. Hydroxyzine
2.60. Lorazepam
Sedatives: 2.61. Diphenhydramine
2.62. Eszopiclone
2.63. Hydroxyzine
2.64. Lorazepam
2.65. Oxazepam
2.66. Temazepam
2.67. Zaleplon
2.68. Zolpidem
Circadian Regulators: 2.69. Melatonin
2.70. Ramelteon
2.71. Tasimelteon
Stimulants: 2.72. Atomoxetine
2.73. Dextroamphetamine
2.74. Lisdexamphetamine
2.75. Methylphenidate
2.76. Mixed Amphetamine Salts: Histaminic Stimulants: 2.77. Armodafinil
2.78. Modafinil
Cognitive Agents: 2.79. Dextromethorphan/quinidine
2.80. Donepizil
2.81. Galantamine
2.82. Memantine
2.83. Rivastigmine
Alpha2-adrenergic Agonists: 2.84. Clonidine
2.85. Guanfacine
Appendices: 3.01. Optimal Antipsychotic Plasma Concentration Ranges
3.02. Optimal Mood Stabilizer Plasma Concentration Ranges
3.03. Formulas for QT Interval Correction
3.04. Common Cytochrome P-450 Inducers and Inhibitors
3.05. Management of Constipation
3.06. Child-Pugh Hepatic Function Scoring
3.07. Loading of Lithium and Valproic Acid
3.08. Treatment of Prolactin Elevation
3.09. A Select List of Foods High in Tyramine
3.10. Medications that Present Risk for Serotonin Syndrome when Combined with MAOIs
3.11. Selected Treatment of Psychomotor Agitation.